Nicholson Nur 4
4 · Apellis Pharmaceuticals, Inc. · Filed May 14, 2026
Research Summary
AI-generated summary of this filing
Apellis (APLS) CTO Nicholson Nur Cashes Out ~695k Shares in Merger
What Happened
- Nicholson Nur, Chief Technical Officer of Apellis Pharmaceuticals (APLS), had a series of merger-related transactions effective May 14, 2026. Under the Biogen merger, many of his shares, RSUs and option-related interests were converted and disposed to the issuer/purchaser. In total the Form 4 reports dispositions totaling about 695,235 shares.
- Per the Merger Agreement, each share tendered was exchanged for $41.00 in cash plus one contingent value right (CVR) that can pay up to $4.00 if certain milestones are met. That implies roughly $28.5 million in cash received (695,235 × $41) and up to about $2.8 million additional potential CVR payments (695,235 × $4). Several derivative awards (options/RSUs) were cancelled or converted into cash and CVRs per the agreement.
Key Details
- Transaction date: May 14, 2026 (Effective Time of the Merger).
- Cash price: $41.00 per share (plus one CVR per share, CVR pays up to $4.00 if milestones achieved).
- Approximate shares disposed: 695,235 (sum of listed dispositions on the Form 4).
- Approximate immediate cash proceeds: ~$28.5 million; potential contingent payments up to ~$2.8 million (if CVR milestones are met).
- Footnotes: Conversions and payouts governed by the Merger Agreement and CVR Agreement (see F1–F13). Some converted RSUs remain subject to time-based vesting/continued service and "double-trigger" provisions; Jan‑2026 performance RSUs were certified at 200% payout (Relative TSR at 93.3rd percentile) per the filing.
- Derivative treatment: Outstanding vested/unvested options and RSUs were automatically cancelled or converted into cash and CVRs per the Merger Agreement (cash‑out rules vary by option exercise price).
- Shares owned after transaction: not specified on the reported Form 4.
- Filing timeliness: Form dated and filed May 14, 2026; no late‑filing flag reported in the filing.
Context
- This was not an open‑market sale but a corporate cash‑out and conversion triggered by the merger with Biogen: many awards were automatically cancelled/converted rather than traded on the market. The CVRs provide contingent upside if specified milestones are achieved; some converted RSU payments remain subject to service/vesting timing under the Merger Agreement.
Insider Transaction Report
Form 4Exit
Nicholson Nur
Chief Technical Officer
Transactions
- Disposition from Tender
Common Stock
[F1][F2][F3]2026-05-14−116,338→ 0 total - Award
Common Stock
[F4][F5]2026-05-14+22,610→ 22,610 total - Disposition to Issuer
Common Stock
[F4][F5]2026-05-14−22,610→ 0 total - Award
Common Stock
[F6][F7][F8]2026-05-14+45,220→ 45,220 total - Disposition to Issuer
Common Stock
[F6][F7][F8]2026-05-14−45,220→ 0 total - Award
Common Stock
[F6][F7][F8]2026-05-14+24,284→ 24,284 total - Disposition to Issuer
Common Stock
[F6][F7][F8]2026-05-14−24,284→ 0 total - Award
Common Stock
[F5][F6]2026-05-14+41,250→ 41,250 total - Disposition to Issuer
Common Stock
[F5][F6]2026-05-14−41,250→ 0 total - Disposition to Issuer
Common Stock
[F9][F10]2026-05-14−5,645→ 0 total - Disposition to Issuer
Common Stock
[F9][F10]2026-05-14−9,754→ 0 total - Disposition to Issuer
Common Stock
[F9][F10]2026-05-14−27,320→ 0 total - Disposition to Issuer
Common Stock
[F9][F10]2026-05-14−45,220→ 0 total - Disposition to Issuer
Stock Option (right to buy)
[F11]2026-05-14−82,500→ 0 totalExercise: $19.39→ Common Stock (82,500 underlying) - Disposition to Issuer
Stock Option (right to buy)
[F11]2026-05-14−115,281→ 0 totalExercise: $29.76→ Common Stock (115,281 underlying) - Disposition to Issuer
Stock Option (right to buy)
[F11]2026-05-14−50,974→ 0 totalExercise: $35.46→ Common Stock (50,974 underlying) - Disposition to Issuer
Stock Option (right to buy)
[F12]2026-05-14−45,000→ 0 totalExercise: $44.90→ Common Stock (45,000 underlying) - Disposition to Issuer
Stock Option (right to buy)
[F13]2026-05-14−35,472→ 0 totalExercise: $52.66→ Common Stock (35,472 underlying) - Disposition to Issuer
Stock Option (right to buy)
[F13]2026-05-14−28,367→ 0 totalExercise: $66.30→ Common Stock (28,367 underlying)
Footnotes (13)
- [F1]Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), by and among Apellis Pharmaceuticals, Inc. (the "Issuer"), Biogen Inc. ("Parent") and Parent's direct wholly-owned subsidiary, Aspen Purchaser Sub, Inc. ("Purchaser"), dated as of March 31, 2026, the shares of common stock, par value $0.0001 per share, of the Issuer (the "Common Stock") that were tendered to Purchaser prior to the expiration time of the tender offer were exchanged for: (i) $41.00 per share of Common Stock, net to the seller in cash, without interest and subject to reduction for any applicable tax withholding (the "Cash Amount"), plus (ii) one contractual, non-transferable contingent value right per share of Common Stock (each, a "CVR"),
- [F10](continued from footnote 9) Subject to the holder's continued service through the vesting dates applicable to the Converted RSU Award under its terms as in effect immediately prior to the Effective Time, all payments in respect of such Converted RSU Award pursuant to the Merger Agreement will vest and become payable at the same time as the underlying Converted RSU Award would have vested and become settled pursuant to its terms and shall otherwise remain subject to the same terms and conditions (including any "double-trigger" vesting provisions applicable to the Converted RSU Award immediately prior to the Effective Time, as extended as provided by the Merger Agreement) as were applicable to the underlying RSU immediately prior to the Effective Time and the terms of the CVR Agreement.
- [F11]Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each outstanding and unexercised option to purchase shares of Common Stock that was vested pursuant to its existing terms or that vested as a result of the transactions contemplated by the Merger Agreement (each, a "Cash-Out Option") and had an exercise price per share that was less than $41.00 (the Cash Amount) was automatically cancelled and converted into the right to receive (i) an amount of cash, without interest and less applicable tax withholding, equal to the product of (x) the total number of shares of Common Stock underlying such option, multiplied by (y) the excess of the Cash Amount over the exercise price per share of such option and (ii) one CVR for each share of Common Stock underlying such option.
- [F12]Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Cash-Out Option that had an exercise price per share that was equal to or greater than the Cash Amount, and less than the sum of (i) $41.00 (the Cash Amount) plus (ii) $4.00 (i.e., the maximum amount payable pursuant to a CVR assuming that the milestones are achieved) (such sum of $45.00, the "Aggregate Amount"), was automatically cancelled and converted into the right to receive one CVR for each share of Common Stock underlying such Cash-Out Option (with any payable milestone payment amounts being reduced by the excess, if any, of the applicable exercise price per share over the Cash Amount).
- [F13]Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each vested or unvested option with an exercise price per share that was equal to or greater than $45.00 (the Aggregate Amount) was cancelled without consideration and will have no further force or effect.
- [F2](continued from footnote 1) which entitles the holder to receive potential payments of up to an aggregate of $4.00 in cash, without interest and subject to reduction for any applicable tax withholding, upon the achievement of certain specified milestones in accordance with the terms and conditions of a contingent value rights agreement (the "CVR Agreement" and the Cash Amount plus one CVR, together, the "Offer Price"). After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into the Issuer (the "Merger"), effective as of the filing and acceptance of the certificate of merger relating thereto on May 14, 2026 (the "Effective Time"), with the Issuer continuing as the surviving corporation (the "Surviving Corporation") and a wholly owned subsidiary of Parent. In the Merger, each share of Common Stock issued and outstanding immediately prior to the Effective Time, subject to certain exceptions,
- [F3](continued from footnote 2) was automatically converted into the right to receive the Offer Price from Purchaser, without interest and subject to reduction for any applicable withholding taxes.
- [F4]Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each outstanding RSU that was not a Cash-Out RSU Award (each, a "Converted RSU Award") that was subject to both a time-based and a performance-based vesting schedule (other than RSUs granted in January 2026 and for which performance-based vesting schedule was based on total shareholder return), was automatically cancelled and converted into the contingent right to receive (i) an amount of cash, without interest and less applicable tax withholding, equal to the product of (x) the total number of shares of Common Stock underlying such Converted RSU Award, as determined based on the target level of performance, multiplied by (y) the Cash Amount and (ii) one CVR for each share of Common Stock underlying such Converted RSU Award.
- [F5](continued from footnote 4) Subject to the holder's continued service through the vesting dates applicable to the Converted RSU Award under its terms as in effect immediately prior to the Effective Time, all payments in respect of such Converted RSU Award pursuant to the Merger Agreement will vest and become payable at the same time as the underlying Converted RSU Award would have vested and become settled pursuant to its terms and shall otherwise remain subject to the same terms and conditions (including any "double-trigger" vesting provisions applicable to the Converted RSU Award immediately prior to the Effective Time, as extended as provided by the Merger Agreement) as were applicable to the underlying RSU immediately prior to the Effective Time and the terms of the CVR Agreement, provided that such payments will no longer be subject to performance-based vesting.
- [F6]Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Converted RSU Award that was granted in January 2026 subject to both a time-based and a performance-based vesting schedule, with the performance-based vesting schedule based on performance with respect to total shareholder return ("TSR") relative to the TSR of the group of companies in the Nasdaq Biotechnology Index ("Relative TSR"), was automatically cancelled and converted into the contingent right to receive (i) an amount of cash, without interest and less applicable tax withholding, equal to the product of (x) the total number of shares of Common Stock underlying such Converted RSU Award, as determined based on the actual performance determined by the compensation committee of the Issuer's board of directors as of May 8, 2026 (which is the latest practicable date prior to the Effective Time),
- [F7](continued from footnote 6) multiplied by (y) the Cash Amount and (ii) one CVR for each share of Common Stock underlying such Converted RSU Award. On May 11, 2026, the compensation committee certified that the Relative TSR as of May 8, 2026 was at the 93.3rd percentile, which resulted in a payout percentage of 200% of target for each such Converted RSU Award, as reported in the table above. Subject to the holder's continued service through the vesting dates applicable to the Converted RSU Award under its terms as in effect immediately prior to the Effective Time, all payments in respect of such Converted RSU Award pursuant to the Merger Agreement will vest and become payable at the same time as the underlying Converted RSU 7. Award would have vested and become settled pursuant to its terms and shall otherwise remain subject to the same terms and conditions (including any "double-trigger" vesting provisions applicable to the Converted RSU Award immediately prior to the Effective Time,
- [F8](continued from footnote 7) as extended as provided by the Merger Agreement) as were applicable to the underlying RSU immediately prior to the Effective Time and the terms of the CVR Agreement, provided that such payments will no longer be subject to performance-based vesting.
- [F9]Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Converted RSU Award that was subject solely to a time-based vesting schedule (including, for the avoidance of doubt, any Converted RSU Award for which the performance period of any applicable performance metric had already ended) was automatically cancelled and converted into the contingent right to receive (i) an amount of cash, without interest and less applicable tax withholding, equal to the product of (x) the total number of shares of Common Stock underlying such Converted RSU Award multiplied by (y) the Cash Amount and (ii) one CVR for each share of Common Stock underlying such Converted RSU Award.
Signature
/s/ David Watson, attorney-in-fact for Nur Nicholson|2026-05-14